Skip to main content

Advertisement

SpringerLink
Log in

CANCER IMMUNOTHERAPY

Splitting signals drives CARs further

  • News & Views
  • Published:

From Nature Cancer

View current issue Submit your manuscript

CAR T cell therapies have made great strides in the clinic; however, multiple hurdles limit the efficacy of this approach for solid tumors. A new study has developed an optimized, dual-targeting CAR T cell that overcomes several of these challenges by enhancing T cell persistence and reducing therapy escape due to antigen loss.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Dual CAR expression with split co-stimulation and a shared CD3ζ domain enhances CAR activity.

BioRender.com

References

  1. Carpenito, C. et al. Proc. Natl Acad. Sci. USA 106, 3360–3365 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Milone, M. C. et al. Mol. Ther. 17, 1453–1464 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. MacIver, N. J., Michalek, R. D. & Rathmell, J. C. Annu. Rev. Immunol. 31, 259–283 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. O’Sullivan, D. et al. Immunity 41, 75–88 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kawalekar, O. U. et al. Immunity 44, 380–390 (2016).

    Article  CAS  PubMed  Google Scholar 

  6. Hirabayashi, K. et al. Nat. Cancer https://doi.org/10.1038//s43018-021-00244-2 (2021).

  7. Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Nat. Biotechnol. 31, 71–75 (2013).

    Article  CAS  PubMed  Google Scholar 

  8. Shah, N. N. et al. Nat. Med. 26, 1569–1575 (2020).

    Article  CAS  PubMed  Google Scholar 

  9. Zah, E., Lin, M. Y., Silva-Benedict, A., Jensen, M. C. & Chen, Y. Y. Cancer Immunol. Res. 4, 498–508 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Heczey, A. et al. Mol. Ther. 25, 2214–2224 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Feucht, J. et al. Nat. Med. 25, 82–88 (2019).

    Article  CAS  PubMed  Google Scholar 

  12. Wherry, E. J. & Kurachi, M. Nat. Rev. Immunol. 15, 486–499 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Guedan, S. et al. J. Clin. Invest. 130, 3087–3097 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Boucher, J. C. et al. Cancer Immunol. Res. 9, 62–74 (2021).

    Article  CAS  PubMed  Google Scholar 

  15. Kofler, D. M. et al. Mol. Ther. 19, 760–767 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA

    Tiffany R. King-Peoples & Avery D. Posey Jr.

  2. Corporal Michael J Crescenz VA Medical Center, Philadelphia, PA, USA

    Avery D. Posey Jr.

Authors
  1. Tiffany R. King-Peoples
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Avery D. Posey Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Avery D. Posey Jr..

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

King-Peoples, T.R., Posey, A.D. Splitting signals drives CARs further. Nat Cancer 2, 873–875 (2021). https://doi.org/10.1038/s43018-021-00257-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-021-00257-x

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation